Katherine L. Nathanson, MD, FACMG, FACP
Katherine L. Nathanson, MD, FACMG, FACP
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
351 BRB II/III
421 Curie Blvd
University of Pennsylvania
Philadelphia, PA 19104
421 Curie Blvd
University of Pennsylvania
Philadelphia, PA 19104
Office: 215-662-4740
Email:
knathans@mail.med.upenn.edu
knathans@mail.med.upenn.edu
Education:
B.A. (Biology)
Haverford College, Haverford, PA, 1987.
M.D.
University of Pennsylvania, Philadelphia, PA, 1993.
Permanent linkB.A. (Biology)
Haverford College, Haverford, PA, 1987.
M.D.
University of Pennsylvania, Philadelphia, PA, 1993.
Description of Research Expertise
Dr. Nathanson’s research focuses on the genetics of human cancer, both germline changes which confer susceptibility to cancer and somatic genetic changes associated with outcome.Her research projects fall into several areas:
1) Identification and characterization of germline genetic changes associated with breast cancer susceptibility. These projects utilize two sample sets, a large clinical database of high risk breast cancer patients and a case-control study of white and black patients with breast cancer. Currently the projects in the laboratory focus on resequencing of BRCA1-associated genes as candidate breast cancer susceptibility genes in patients with high risk breast cancer and studying copy number variation as associated with potential susceptibility to high risk breast cancer in families with multiple cases of breast cancer.
2) Identification of genetic changes associated with testicular cancer susceptibility in case-control sample set. Dr. Nathanson recently completed a successful genome wide association study in testicular cancer, and is in the process of designing and doing a number of follow-up studies.
3) Identification of somatic genetic markers in melanoma as determinants of response to therapy. The projects in the laboratory focus on several aspects of melanoma genetics including genotyping patients to determine targeted therapy selection, using genetics and genomics to sub-set melanomas, as well as understand response to therapy, and identify novel genes important in melanoma progression.
Selected Publications
Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J, Albano A, Chen C, Starr JR, Rader DJ, Godwin AK, Reilly MP, Hakonarson H, Schwartz SM, Nathanson KL.: Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41(7): 811-815, Jul 2009.Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL: Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7(9): 2876-2883, Sep 2008.
Gordon JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rahmell K, Keith B, Simon MC, Nathanson KL: HIFα effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6): 423-4, Dec 2008.
Dalla Palma M, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL: The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high risk breast cancer families. Cancer Res 68(17): 7006-7014, Sep 2008.
Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL.: Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 68(14): 5743-5752, Jul 2008.
Tchou J, Ward MR, Volpe P, Dalla Palma M, Medina CA, Sargen M, Sonnad S, Godwin AK, Daly M, Winchester D, Garber J, Weber BL, Domchek S, Nathanson KL: Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clin Breast Cancer 7(8): 627-633, Jun 2007.
Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaïti-Pellié C, Heidenreich A, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Oosterhuis JW, Gillis AJ, Looijenga LH, Guilford P, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Rudd M, Huddart R, Crockford GP, Forman D, Oliver DT, Einhorn L, Weber BL, Kramer J, McMaster M, Greene MH, Pike M, Cortessis V, Chen C, Schwartz SM, Bishop DT, Easton DF, Stratton MR, Rapley EA: The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. Am J Hum Genet 77(6): 1034-1043, Dec 2005.
Redston M, Nathanson KL, Yuan Z Q, Neuhausen S L,* Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King M C, Woodage T, Brody L C, Godwin A, Warner E, Weber B, Foulkes W, Offit K: The APC I1307K allele and breast cancer risk Nature Genetetics 20(1): 13-14, Sep 1998.